COMPARISON OF HYPOMETHYLATING AGENTS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME: RETROSPECTIVE ANALYSIS, SINGLE CENTER EXPERIENCE

被引：0
|
作者：
Unal, A. [1 ]
Keni, N. [1 ]
Yildizhan, E. [1 ]
Turak, E. [1 ]
Kaynar, L. [1 ]
Zararsiz, G. [1 ]
Uysal, E. [1 ]
Eser, B. [1 ]
Cetin, M. [1 ]
机构：
[1] Erciyes Univ, Dept Hematol, Kayseri, Turkey
来源：
LEUKEMIA RESEARCH | 2017年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OP-22
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [21] PEDIATRIC MYELODYSPLASTIC SYNDROME: EXPERIENCE FROM A SINGLE CENTER
    Cetin, M.
    Unal, S.
    Bayhan, T.
    Aytac, S.
    Kuskonmaz, B.
    Tavil, B.
    Uckan-Cetinkaya, D.
    Tuncer, M.
    Gumruk, F.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S323 - S323
  • [22] HYPOMETHYLATING AGENTS IN THE TREATMENT OF UNFIT ACUTE MYELOID LEUKEMIA PATIENTS: A REAL LIFE EXPERIENCE IN A SINGLE CENTER
    Piccioni, A. L.
    Anaclerico, B.
    Borza, P. Anticoli
    Bongarzoni, V.
    Cedrone, M.
    Fenu, S.
    Crescenzi, S. Leonetti
    Ronci, B.
    Bagnato, A.
    Chierichini, A.
    HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [23] LONG-TERM EXPERIENCE OF TREATMENT WITH HYPOMETHYLATING AGENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOBLASTIC LEUKEMIA (AML)
    Costa, S.
    Marin, M.
    Castellot, A.
    Vidal, E.
    Uribe, M. S.
    Lopez, P.
    Ibanez, F.
    Mena, A.
    Roig, M.
    Perez, P.
    Cervero, A.
    Linares, M.
    HAEMATOLOGICA, 2019, 104 : 439 - 439
  • [24] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [25] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
  • [26] Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes
    Venugopal, Sangeetha
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S73 - S76
  • [27] Hypomethylating agents use in acute myeloid leukemia: A single-center experience
    Bodepudi, Sravan Kumar
    Devdas, Santhosh Kumar
    Maka, Vinayak V.
    Palassery, Rasmi
    Hiregoudar, Sumathi S.
    Kilara, Nalini
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (02) : 202 - 208
  • [28] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
    Finelli, Carlo
    Follo, Matilde Y.
    Stanzani, Marta
    Parisi, Sarah
    Clissa, Cristina
    Mongiorgi, Sara
    Barraco, Marilena
    Cocco, Lucio
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
  • [29] Role of Hypomethylating Agents in the Treatment of AML: Retrospective Study at a Tertiary Care Center
    Naik, Ramavath Devendra
    Kumar, Lalit
    Baa, Annie K.
    Mittal, Abhenil
    Sahitya, Dsk
    Sahoo, Ranjit K.
    Singh, Vishwajeet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S232 - S233
  • [30] The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm
    Merkel, Drorit G.
    Nagler, Arnon
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (06) : 665 - 676
12345